14 completed, 12 recruiting, 6 active not recruiting, 6 terminated. 29 Phase 2, 19 Phase 1, 2 Not applicable, 2 Phase 3.
Follow Vyxeos: new trials by email Literature Review of Vyxeos trials Research Report on Vyxeos
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment Cytarabine, Venetoclax, CPX-351 - Leukemia, Myeloid, Acute | Phase 2 | Not yet recruiting | Eastern Cooperative Oncology Group | 184 | 2024-10-23 | 2024-07-03 |
| Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 335 | 2024-09-25 | 2026-10-27 |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2000 | 2024-06-18 | 2026-10-27 |
| Tazemetostat and Palbociclib With CPX-351for R/R AML Tazemetostat, Liposome-encapsulated Daunorubicin-Cytarabine, Bone Marrow Aspiration and Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | Thomas Jefferson University | 24 | 2023-08-28 | 2026-03-12 |
| A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection (cytarabine: daunorubicin) liposome for injection, Vyxeos - Acute Myeloid Leukemia | Not applicable | Unknown | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 36 | 2023-08-25 | 2023-09-21 |
| A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat Anti-CD123 ADC IMGN632, Bone Marrow Aspiration and Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Children's Oncology Group | 2023-08-01 | 2023-09-01 | |
| Phase IB/II of CPX-351 for Relapse Prevention in AML CPX-351 - Acute Myeloid Leukemia (AML) in Remission | Phase 1 / Phase 2 | Recruiting | Georgetown University | 24 | 2023-05-22 | 2026-03-23 |
| CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML Vyxeos, Gemtuzumab Ozogamicin - Acute Myeloid Leukemia | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 18 | 2023-02-16 | 2026-02-27 |
| Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 49 | 2022-08-24 | 2026-06-30 |
| Vyxeos for Induction of Low- or Intermediate-risk. Vyxeos, Mylotarg - Leukemia, Myeloid, Acute | Phase 2 | Active not recruiting | Shaare Zedek Medical Center | 20 | 2022-08-07 | 2026-10-08 |
| Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML Gilteritinib, Vyxeos - Acute Myeloid Leukemia With FLT3/ITD Mutation | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 22 | 2022-02-25 | 2025-12-05 |
| CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 1 | 2021-08-09 | 2024-05-23 |
| CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 2 | Completed | Roswell Park Cancer Institute | 21 | 2021-07-29 | 2026-09-08 |
| Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 1 | 2021-05-21 | 2026-05-20 |
| Venetoclax + Azacitidine vs. Induction Chemotherapy in AML Cytarabine, Idarubicin, Daunorubicin - Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Massachusetts General Hospital | 172 | 2021-05-20 | 2026-05-12 |
| Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction Liposome-encapsulated Daunorubicin-Cytarabine - Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Persistent Disease | Phase 1 / Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 28 | 2021-01-29 | 2026-09-09 |
| CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Ivosidenib, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia With Gene Mutations, Myelodysplastic Syndrome | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2020-12-30 | 2026-08-25 |
| Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients Daunorubicin Cytarabine liposome for injection, Vyxeos、Daunorubicin Cytarabine liposome for injection - Acute Myeloid Leukemia | Not applicable | Unknown | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 16 | 2020-09-04 | 2021-06-09 |
| Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia. Fludarabine, Vyxeos - Acute Myeloid Leukemia, Adult, AML | Phase 2 | Terminated | University of California, San Diego | 2 | 2020-08-05 | 2022-09-22 |
Showing 20 of 44. Sign in to see all of them.
Leukemia, Myeloid, Acute (36) · Myelodysplastic Syndromes (6) · Myeloproliferative Disorders (5) · Leukemia, Myelomonocytic, Chronic (3) · Burkitt Lymphoma (2) · Leukemia (2) · Leukemia, Monocytic, Acute (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2) · Hematologic Neoplasms (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Lymphoid (1) · Neoplasm, Residual (1) · Polycythemia Vera (1) · Primary Myelofibrosis (1)
M.D. Anderson Cancer Center (7) · Jazz Pharmaceuticals (4) · National Cancer Institute (NCI) (4) · Children's Oncology Group (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (2) · Fred Hutchinson Cancer Center (2) · Jonsson Comprehensive Cancer Center (2) · Ohio State University Comprehensive Cancer Center (2) · Children's Hospital Medical Center, Cincinnati (1) · Eastern Cooperative Oncology Group (1) · GWT-TUD GmbH (1) · Georgetown University (1) · Massachusetts General Hospital (1) · Novartis Pharmaceuticals (1)
United States (35) · Canada (5) · Puerto Rico (3) · China (2) · Australia (1) · Austria (1) · Germany (1) · Israel (1) · United Kingdom (1)
Caspian Oliai, MD (2) · Onyee Chan, MD (2) · Todd M Cooper (2) · Amir T Fathi, MD (1) · Bijal Shah, M.D. (1) · Branko Cuglievan (1) · Charles Craddock, Professor (1) · Chezi Ganzel, DR (1) · Courtney DiNardo, MD (1) · Ehab Atallah, MD (1) · Ehab L Atallah (1) · Ellen K Ritchie, MD (1) · Eunice Wang, MD (1) · Filippo Milano (1) · Ghayas Issa (1)
PMID 33208914, PMID 32401633, PMID 33843815, PMID 35450817, PMID 36892565, PMID 36902217, PMID 37946611, PMID 38000343, PMID 38107263, PMID 38473278, PMID 38947228, PMID 39418644, PMID 40298352, PMID 40401707, PMID 40932876, PMID 42497367, PMID 42559085, PMID 42685316, PMID 42835577
U10CA180886 (3), U10CA180888 (2), 2018 (1), P30CA036727 (1), U10CA180820 (1), UM1CA186712 (1)